Lv4
590 积分 2022-11-24 加入
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
15小时前
待确认
Cancer burden and control in China: landscape, trends and challenges
1天前
待确认
Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial
28天前
已完结
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
1个月前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
1个月前
已完结
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
1个月前
已完结
Multiple myeloma
1个月前
已关闭
Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004–2008)
1个月前
已完结
First 20 years with recombinant FVIIa (NovoSeven)
1个月前
已完结
Patients with haemophilia A with inhibitors in China: a national real‐world analysis and follow‐up
1个月前
已完结
皖公网安备34019202002308
